Stock A128940 HANMI PHARM. CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

All News Hanmi Pharm. Co., Ltd.

Equities

A128940

KR7128940004

End-of-day quote Korea S.E.
Other stock markets
 03:30:00 17/06/2024 am IST 		5-day change 1st Jan Change
2,80,500 KRW +0.90% Intraday chart for Hanmi Pharm. Co., Ltd. -1.06% -20.43%
16/05 Hanmi Pharm. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
08/05 Invion Partners with Hanlim Pharma for Glioblastoma Treatment MT

All News

Search
See the results
Unlock all the news: Be the first to know and act before the market!
100% Free Registration
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Invion Partners with Hanlim Pharma for Glioblastoma Treatment
MT
Hanmi Pharm Q1 Profit Surges 27.5%, Sales Up 11.8%
MT
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.
CI
Aptose Biosciences Inc. announced that it expects to receive $4 million in funding from Hanmi Pharm. Co., Ltd.
CI
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
CI
Allergic Rhinitis Pipeline, Clinical Trials, Key Companies
AQ
Hanmi Pharm's Q3 Income Surges 94%
MT
Allergic Rhinitis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated)
AQ
AffaMed Therapeutics Announces Clinical Trial Application Approval in Mainland China for Risuteganib First-in-Class Candidate for the Treatment of Intermediate Dry AMD
AQ
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
CI
Aptose Biosciences Inc. announced that it expects to receive $6.999998 million in funding from Hanmi Pharm. Co., Ltd.
CI
Hanmi Pharm's Net Income Declines in Q2
MT
Assertio Holdings, Inc. (NasdaqCM : ASRT) completed the acquisition of Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI).
CI
Hanmi Pharm. Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Hanmi Pharm's Net Income Climbs in Q1
MT
Assertio Holdings, Inc. (NasdaqCM : ASRT) entered into a definitive agreement to acquire Spectrum Pharmaceuticals, Inc. (NasdaqGS : SPPI) for approximately $250 million.
CI
Hanmi Pharm. Co., Ltd.'s Combination Drug for Dyslipidemia Treatment, 'Rosuzet': Confirms Non-inferiority Efficacy and Safety Compared to Monotherapy in The Lancet' & 'European Heart Journal
CI
Advanced Gastric Carcinoma Pipeline Assessment of Active Pipeline Assets Segmented by Stage, Product Type, Route of Administration, and Molecule Type
AQ
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. A128940 Stock
  4. News Hanmi Pharm. Co., Ltd.